Showing 1-30 of 42 results for "1499403"
S N Verouti et al.
Nephron. Experimental nephrology, 122(1-2), 36-50 (2013-04-04)
Vitamin D is beneficial in human and experimental chronic kidney disease, the leading cause of which is diabetic nephropathy. Vitamin D through its receptor, VDR, provides renal protection in diabetic nephropathy, but limited data exist about its effect on podocytes....
Douglas K Atchison et al.
American journal of physiology. Renal physiology, 305(8), F1109-F1117 (2013-08-09)
1, 25-Dihydroxycholechalciferol (calcitriol) and 19-nor-1, 25-dihydroxyvitamin D2 (paricalcitol) are vitamin D receptor (VDR) agonists. Previous data suggest VDR agonists may actually increase renin-angiotensin activity, and this has always been assumed to be mediated by hypercalcemia. We hypothesized that calcitriol and...
Julia A Lawrence et al.
Cancer biology & therapy, 14(6), 476-480 (2013-06-14)
The vitamin D hormone, [1,25(OH) 2D, calcitriol], inhibits proliferation and angiogenesis in breast cancer but its therapeutic use is limited by hypercalcemia. Synthetic analogs of 1,25(OH) 2D that are less calcemic, such as paricalcitol (19-nor-1,25-Dihydroxyvitamin D 2), are used to...
A Azak et al.
Annals of the Royal College of Surgeons of England, 95(7), 489-494 (2013-10-12)
Despite the developments in modern medicine, acute renal injury is still a challenging and common health problem. It is well known that ischaemia and reperfusion takes place in pathological mechanisms. Efforts to clarify the pathophysiology and interventions to improve outcomes...
Chang Seong Kim et al.
PloS one, 8(5), e63186-e63186 (2013-05-22)
4-Hydroxy-2-hexenal (HHE), the aldehyde product of lipid peroxidation, may be responsible for the pathogenesis of progressive renal disease. Recently, paricalcitol (19-nor-1,25-dihydroxyvitamin D2) was shown to be renoprotective through its anti-inflammatory and antifibrotic effects in various experimental nephropathy models. In this...
Mario Cozzolino et al.
Contributions to nephrology, 171, 161-165 (2011-06-01)
Cardiovascular (CV) morbidity and mortality are significantly higher in patients with chronic kidney disease (CKD). Mineral metabolism disorders, such as hyperphosphatemia, hypocalcemia, and vitamin D deficiency, have been deeply associated not only with bone disease, but also with vascular calcification...
Antonio Bellasi et al.
Blood purification, 36(1), 12-16 (2013-06-06)
Chronic kidney disease mineral bone disorders (CKD-MBD) encompass laboratory, vascular and bone abnormalities that might portend a poor prognosis in CKD. In spite of a great effort in elucidating the CKD-MBD natural history and pathogenesis, the underlying mechanisms are still...
Juan F Navarro-González et al.
Journal of clinical pharmacology, 53(4), 421-426 (2013-02-22)
Inflammation is a strong predictor of increased morbidity and mortality in hemodialysis (HD) patients. Paricalcitol, a selective vitamin D receptor activator used for prevention and treatment of secondary hyperparathyroidism, has shown anti-inflammatory properties in experimental studies, although clinical data are...
Soochan Bae et al.
Journal of applied physiology (Bethesda, Md. : 1985), 114(8), 979-987 (2013-02-23)
Accumulating evidence suggests that vitamin D deficiency plays a crucial role in heart failure. However, whether vitamin D signaling itself plays an important role in cardioprotection is poorly understood. In this study, we examined the mechanism of modulating vitamin D...
Amit Sharma et al.
Journal of medical economics, 16(9), 1129-1136 (2013-07-10)
The objective of this analysis was to compare costs of paricalcitol or cinacalcet plus low dose vitamin D, and of phosphate binders, in patients in the IMPACT SHPT study; and to extrapolate those to estimate expected annual maintenance costs. IMPACT...
Josefin Axelsson et al.
American journal of physiology. Renal physiology, 305(3), F237-F243 (2013-05-10)
Systemic infusions of ANG II rapidly induce large, dynamic increases in the permeability of the glomerular filtration barrier (GFB) in rats. After binding to its receptor(s), ANG II generates reactive oxygen species (ROS) and produces Ca²⁺ influx into cells, leading...
Michelle M Duffy et al.
American journal of physiology. Renal physiology, 307(12), F1412-F1426 (2014-10-24)
Mesenchymal stem cells (MSCs) suppress T helper (Th)17 cell differentiation and are being clinically pursued for conditions associated with aberrant Th17 responses. Whether such immunomodulatory effects are enhanced by coadministration of MSCs with other agents is not well known. In...
Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
Jeannette Mansour et al.
Nature clinical practice. Nephrology, 3(4), E2-E2 (2007-03-29)
H Amer et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 13(6), 1576-1585 (2013-04-23)
Postkidney transplant hyperparathyroidism is a significant problem. Vitamin D receptor agonists are known to suppress parathyroid hormone (PTH) secretion. We examined the effect of oral paricalcitol on posttransplant secondary hyperparathyroidism by conducting an open label randomized trial in which 100...
Dean M Robinson et al.
Drugs, 65(4), 559-576 (2005-03-01)
Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention...
Mario Cozzolino et al.
Current vascular pharmacology, 6(2), 148-153 (2008-04-09)
Hemodialysis (HD) patients are commonly affected by secondary hyperparathyroidism (SHPT), in which 3 well-known factors are usually involved: hypocalcemia, hyperphosphatemia and calcitriol deficiency. Classically, high parathyroid hormone (PTH) levels cause bone-associated diseases, such as osteitis fibrosa and renal osteodystrophy, but...
I Sahin et al.
European review for medical and pharmacological sciences, 18(19), 2895-2902 (2014-10-24)
The effect of vitamin D and renin-angiotensin-aldosterone system blockade medications in pathophysiology of contrast induced nephropathy (CIN) is controversial. The effects of paricalcitol (active vitamin D analogue) and losartan treatments in an experimental model of CIN were investigated in this...
Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients.
Esther Gonzalez et al.
Transplantation, 95(7), e49-e52 (2013-04-03)
Darko Duplancic et al.
Clinical interventions in aging, 8, 149-156 (2013-02-23)
The ubiquitous distribution of vitamin D receptors in the human body is responsible for the pleiotropic effects of vitamin D-receptor activation. We discuss the possible beneficial effects of a selective activator of vitamin D receptor, paricalcitol, on the cardiovascular system...
Sunil K Halder et al.
Reproductive sciences (Thousand Oaks, Calif.), 21(9), 1108-1119 (2014-06-14)
We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluations in appropriate uterine fibroid cells and animal models. We found that paricalcitol...
Daniel W Coyne et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 28(9), 2260-2268 (2013-06-22)
Chronic kidney disease (CKD) is associated with elevations in serum phosphate, calcium-phosphorus product and bone-specific alkaline phosphatase (BAP), with attendant risks of cardiovascular and bone disorders. Active vitamin D can suppress parathyroid hormone (PTH), but may raise serum calcium and...
M Cozzolino et al.
Clinical nephrology, 71(6), 593-601 (2009-05-29)
Modern strategies to prevent secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients give great relevance to vitamin D replacement therapy. However, a sound approach to treatment requires taking into account many factors, including stage of CKD, underlying renal disorder...
Angela Yee-Moon Wang et al.
Journal of the American Society of Nephrology : JASN, 25(1), 175-186 (2013-09-21)
Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitamin D on patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebo-controlled trial to determine whether oral activated vitamin D reduces left...
Flávio N F Reis
Kidney international, 77(12), 1055-1057 (2010-05-29)
The management of cyclosporine A (CsA)-induced nephrotoxicity remains one of the main challenges in kidney transplantation. The animal study by Park et al. proposes that paricalcitol, a vitamin D analog with renoprotective actions reported in other conditions, attenuates CsA-induced kidney...
Jun Cheng et al.
Clinical journal of the American Society of Nephrology : CJASN, 7(3), 391-400 (2012-01-10)
Observational data indicate that newer vitamin D compounds such as paricalcitol can suppress serum intact parathyroid hormone (iPTH) and reduce proteinuria in patients with CKD. To systematically evaluate the efficacy and safety of paricalcitol for CKD, we conducted a meta-analysis...
Mario Cozzolino et al.
Expert opinion on pharmacotherapy, 9(6), 947-954 (2008-04-02)
Secondary hyperparathyroidism (SHPT) is common in chronic kidney disease (CKD) patients. Classically, SHPT is induced by hypocalcemia, hyperphosphatemia, and calcitriol deficiency, that cause not only renal osteodystrophy but also systemic toxicity, particularly cardiovascular disease. Treatment with calcitriol, the active form...
Christopher A Dyer
Expert opinion on drug safety, 12(5), 717-728 (2013-04-30)
Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD). Beyond skeletal complications, uncontrolled SHPT is associated with cardiovascular mortality. Vitamin D receptor activators (VDRAs) are a mainstay of therapy for SHPT; however, use is limited by hypercalcemia, though...
Stefania Pacini et al.
Nutrients, 5(6), 2076-2092 (2013-06-12)
Cardiovascular diseases are more prevalent in patients with chronic kidney disease than in the general population and they are considered the leading cause of death in patients with end-stage renal disease. The discovery that vitamin D3 plays a considerable role...
Celestino Piñera-Haces et al.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 33(1), 77-84 (2013-02-01)
The deficit of 25-hydroxyvitamin D (25OHD) associated with secondary hyperparathyroidism (SHPT) is a frequent finding in chronic kidney disease (CKD) patients on haemodialysis (HD). These events are associated with increased morbidity and mortality rates of cardiovascular (CV) origin. Adequate 25OHD...
Tianzhao Han et al.
BioMed research international, 2013, 320560-320560 (2013-03-20)
Previous studies have demonstrated the safety and efficacy of using Paricalcitol for the treatment of secondary hyperparathyroidism (SHPT) in patients on dialysis. The aim of the current meta-analysis was to assess the safety and efficacy of Paricalcitol for the management...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.